Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2013 Archives

Dec 9, 2013
Seeking indication for prevention of chemotherapy-induced nausea and vomiting

Helsinn Group and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) accepted for review the...

More
Dec 5, 2013

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual...

More
Dec 4, 2013

Eisai Inc. announced today that five abstracts highlighting new study results will be presented during the 2013 San Antonio Breast Cancer...

More
Dec 3, 2013
"Medikidz Explain Epilepsy" Aims to Help Children Better Understand the Disease

Eisai Inc., a leader in the epilepsy community, is proud to announce the availability of a first-of-its-kind comic book in the U.S. designed to...

More
Nov 25, 2013

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has become a signatory to the Tuberculosis Drug...

More
Nov 18, 2013
Representatives Will Use Educational Tool for Up to 65,000 Physicians

Eisai and BusinessOne Technologies announced today that Eisai Inc. is using the Maestro Market Access Mobile™ application...

More
Nov 13, 2013

Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that five abstracts highlighting new data analyses from...

More
Nov 13, 2013
Eisai to Convene Multidisciplinary Expert Panel in an Effort to Combat Growing Epidemic

A new survey conducted by Eisai Inc., in partnership with the Obesity Action Coalition (OAC) and The Obesity Society (TOS), reveals a...

More
Nov 8, 2013

Eisai Inc. announced today that ACIPHEX® Sprinkle™ Delayed-Release Capsules 5mg and 10mg will be available to eligible patients by...

More
Nov 7, 2013
-- Collaboration to Focus on Global Commercialization and Development for Weight Management and Potential New Indications --

SAN DIEGO, CA and WOODCLIFF LAKE, NJ, November 7, 2013 – Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the BELVIQ® (lorcaserin HCl) marketing...

More
Nov 1, 2013
Award supports vital research to understand rare and severe form of epilepsy

The Child Neurology Foundation (CNF) and Eisai Inc. today announced that the first annual Michael SanInocencio Lennox-Gastaut Syndrome (LGS)...

More
Oct 28, 2013
FIRST SHIPMENT TO BENEFIT MORE THAN 6 MILLION PEOPLE IN 4 ENDEMIC COUNTRIES

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has begun the free supply of...

More
Oct 15, 2013
BELVIQ® Sales Force to Double in Size by December 2013

Eisai Inc. announced today that, as part of its long-term marketing strategy, the company will expand its sales force by adding more than 200...

More
Oct 9, 2013
Cornucopia Cancer Support Center™ Joins Forces with the Eisai Women’s Oncology Program - Magnolia™, CancerCare®, Cancer Support Community(SM) and Meals On Wheels Association of America™ to Help Ease the Stress of Those Living with Breast Cancer

Woodcliff Lake, NJ, October 7, 2013- Magnolia Meals at HomeTM, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in...

More
Oct 9, 2013

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1 clinical study...

More
Oct 1, 2013
Eisai, CancerCare®, and Cancer Support Community(SM) Launch meal Trains(SM) sponsored by Magnolia™ During Breast Cancer Awareness Month; Campaign Aims to Drive 1,000 New meal Trains in October

Eisai Inc., along with collaborators CancerCare and Cancer Support Community, have announced meal TrainsSM sponsored by Magnolia™, which aim...

More
Sep 16, 2013
- Companies Initiate Multiple Co-discovery Programs for First-in-class Targets in Oncology -

H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology...

More
Sep 12, 2013
The BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin HCl) CIV Patients

Eisai Inc. today announced the availability of the BELIEVE EVERYDAY SUPPORTSM program to provide free, comprehensive support and savings for BELVIQ

More
Aug 29, 2013

Eisai Inc. announced that the company has recently entered into a non-exclusive licensing agreement in the United States with a manufacturer of...

More
Aug 19, 2013
Epilepsy Drug Still Not Available to Patients 10 Months After FDA Approval

Eisai Inc. filed a petition today with the U.S. Court of Appeals for the District of Columbia asking the court to direct the Drug Enforcement...

More
Aug 15, 2013

Eisai Inc. announced today the launch of a new website to provide employers with an educational resource for information about obesity...

More
Aug 8, 2013

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound...

More
Jul 8, 2013
The Eisai Women’s Oncology Program - MagnoliaTM, CancerCare®, Cancer Support CommunitySM and Meals On Wheels Association of AmericaTM Are Working Together to Help Ease the Stress of Those Living with Breast Cancer in New Jersey

Woodcliff Lake, NJ, July 8, 2013- Magnolia Meals at Home™, a program that delivers nutritious meals at no-cost to patients living with breast cancer and their families, is now available in Essex...

More
Jul 3, 2013
Earns V2.2 Gold Certification for New Construction

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot pilot plant...

More
Jun 20, 2013

Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3...

More
 

print email rss